Get the Stockscreener App
5.74
9.46%
-0.60
After Hours:
5.74
Galectin Therapeutics Inc stock is traded at $5.74, with a volume of 774.10K.
It is down -9.46% in the last 24 hours and up +1.95% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$6.34
Open:
$6.28
24h Volume:
774.10K
Relative Volume:
2.14
Market Cap:
$370.07M
Revenue:
-
Net Income/Loss:
$-45.08M
P/E Ratio:
-7.863
EPS:
-0.73
Net Cash Flow:
$-33.68M
1W Performance:
+0.17%
1M Performance:
+1.95%
6M Performance:
+341.54%
1Y Performance:
+172.68%
1-Day Range:
$5.67
$6.66
1-Week Range:
$5.31
$6.66
52-Week Range:
$0.726
$6.66
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
5.74 | 406.18M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Galectin Therapeutics (NASDAQ:GALT) Major Shareholder Fund L.P. 10X Sells 30,000 Shares - MarketBeat
Prepare Yourself for Liftoff: Galectin Therapeutics Inc (GALT) - Setenews
How Galectin Therapeutics Inc. (PHPN) stock reacts to Fed tighteningJuly 2025 Volume & Daily Growth Stock Tips - Newser
Is Galectin Therapeutics Inc. (PHPN) stock a contrarian opportunityBear Alert & Safe Capital Growth Stock Tips - Newser
10x fund sells Galectin therapeutics (GALT) shares worth $851,700 By Investing.com - Investing.com India
10x fund sells Galectin therapeutics (GALT) shares worth $851,700 - Investing.com
Will Galectin Therapeutics Inc. (PHPN) stock benefit from commodity supercycleJuly 2025 Rallies & Short-Term High Return Strategies - Newser
Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data (NASDAQ:GALT) - Seeking Alpha
Is Galectin Therapeutics Inc. (PHPN) stock a buy on weaknessWeekly Trade Review & Community Consensus Stock Picks - Newser
Is Galectin Therapeutics Inc. (PHPN) stock undervalued historicallyQuarterly Risk Review & High Win Rate Trade Alerts - Newser
Will Galectin Therapeutics Inc. (PHPN) stock rise with strong economy2025 Stock Rankings & Growth Oriented Trading Recommendations - Newser
Can Galectin Therapeutics Inc. (PHPN) stock double in coming yearsQuarterly Profit Report & Daily Growth Stock Tips - Newser
Galectin Therapeutics Reveals Promising NAVIGATE Trial Results - TipRanks
Galectin Therapeutics Inc Presents NAVIGATE Trial Results - TradingView
Will Galectin Therapeutics Inc. (PHPN) stock sustain bullish trend into 2025Quarterly Growth Report & High Accuracy Investment Entry Signals - Newser
Will Galectin Therapeutics Inc. (PHPN) stock beat international competitionJuly 2025 Snapshot & Stepwise Entry/Exit Trade Alerts - Newser
How big funds are accumulating Galectin Therapeutics Inc. (PHPN) stockMarket Activity Report & Weekly Chart Analysis and Guides - Newser
Why Galectin Therapeutics Inc. stock is favored by pension fundsJuly 2025 Review & Free Technical Confirmation Trade Alerts - BỘ NỘI VỤ
Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200 Day Moving AverageTime to Sell? - MarketBeat
The growth track for Galectin Therapeutics Inc (GALT) has changed recently - Setenews
Will Galectin Therapeutics Inc. stock sustain high P E ratiosTrade Volume Summary & Weekly High Potential Alerts - BỘ NỘI VỤ
Galectin Therapeutics: NAVIGATE Data Validates The Fibrosis Thesis - Seeking Alpha
Wealthspire Advisors LLC Buys 81,144 Shares of Galectin Therapeutics Inc. $GALT - MarketBeat
How Galectin Therapeutics Inc. stock reacts to Fed rate cutsDip Buying & Stepwise Trade Execution Plans - newser.com
How Galectin Therapeutics Inc. (PHPN) stock trades pre earnings2025 Support & Resistance & Fast Entry Momentum Trade Alerts - newser.com
What sentiment indicators say about Galectin Therapeutics Inc. stockTrade Analysis Summary & Real-Time Buy Zone Alerts - newser.com
Applying Elliott Wave Theory to Galectin Therapeutics Inc.Quarterly Profit Review & Step-by-Step Trade Execution Guides - newser.com
Will Galectin Therapeutics Inc. (PHPN) stock hit analyst forecasts2025 Institutional Moves & Breakout Confirmation Alerts - newser.com
Galectin Therapeutics Insider Sold Shares Worth $478,849, According to a Recent SEC Filing - MarketScreener
CFO Callicutt Sells 77,920 ($478.8K) Of Galectin Therapeutics Inc [GALT] - TradingView
CEO Lewis Sells 22,463 ($136.4K) Of Galectin Therapeutics Inc [GALT] - TradingView
[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity - Stock Titan
What valuation multiples suggest for Galectin Therapeutics Inc. stock2025 Fundamental Recap & Consistent Profit Alerts - newser.com
Holdings of Galectin Therapeutics Inc (GALT) are aligned with the stars - Setenews
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galectin Therapeutics Inc Stock (GALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| 10X Fund, L.P. | 10% Owner |
Dec 02 '25 |
Sale |
5.47 |
30,000 |
164,100 |
5,802,207 |
| LEWIS JOEL | President and CEO |
Nov 17 '25 |
Option Exercise |
2.39 |
15,680 |
37,475 |
848,272 |
| LEWIS JOEL | President and CEO |
Nov 18 '25 |
Option Exercise |
2.39 |
6,783 |
16,211 |
839,375 |
| LEWIS JOEL | President and CEO |
Nov 17 '25 |
Sale |
6.04 |
15,680 |
94,643 |
832,592 |
| LEWIS JOEL | President and CEO |
Nov 18 '25 |
Sale |
6.15 |
6,783 |
41,723 |
832,592 |
| CALLICUTT JACK W | Chief Financial Officer |
Nov 18 '25 |
Option Exercise |
1.64 |
46,310 |
75,851 |
35,714 |
| CALLICUTT JACK W | Chief Financial Officer |
Nov 17 '25 |
Option Exercise |
1.38 |
31,610 |
43,706 |
27,315 |
| CALLICUTT JACK W | Chief Financial Officer |
Nov 18 '25 |
Sale |
6.22 |
46,310 |
288,187 |
7,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Nov 17 '25 |
Sale |
6.03 |
31,610 |
190,662 |
7,614 |
| Jamil Khurram | Chief Medical Officer |
Nov 13 '25 |
Option Exercise |
2.17 |
99,250 |
215,038 |
45,979 |
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):